Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole Monotherapy or Combination with Sertraline in Adults with PTSD
NCT03033069Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brexpiprazole orally disintegrating tablet in post-traumatic stress disorder (PTSD) (4 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Change From Baseline in Clinician-Administered Post-traumatic Stress Disorder Scale for DSM-5 Total Score at 12 weeks. Started Jan 2017; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03033069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03033069.